Brief: Gain Therapeutics Announces Positive Results From Single Ascending Dose Part Of The Phase 1 Clinical Trial Of GT-02287
24/04/2024 15:29
April 24 (Reuters) - Gain Therapeutics Inc GANX.O :
* GAIN THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM THE
SINGLE
ASCENDING DOSE (SAD) PART OF THE PHASE 1 CLINICAL TRIAL OF
GT-02287, A NOVEL GCASE-TARGETING SMALL MOLECULE THERAPY FOR
GBA1 PARKINSON’S DISEASE
Source text for Eikon: ID:nGNXb4ZhtM
Further company coverage: GANX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gain Therapeutics
See all newsU.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Gain Therapeutics climbs on narrower-than-expected quarterly loss
Gain Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall